IO-103 is under clinical development by IO Biotech and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma). According to GlobalData, Phase II drugs for Basal Cell Carcinoma (Basal Cell Epithelioma) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IO-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IO-103 overview
IO-103 is under development for the treatment of basal cell carcinoma, essential thrombocythemia, polycythemia vera and multiple myeloma. It is a XX-mer PD-L1-derived peptide vaccine targeting PD-L1 administered by the subcutaneous route. The vaccine candidate is developed based on T-win technology. It was also under development for melanoma and follicular lymphoma.
IO Biotech overview
IO Biotech is a biotechnology company, which develops disruptive immune modulating anti-cancer drugs. The company is investigating IO102 vaccine, against non-small cell lung cancer (NSCLC); IO130, a PD-L1 inhibitor targeting basal cell carcinoma of the skin; IO112 vaccine, to treat solid tumors; IO140, an immune modulatory vaccine containing a single CCL22 derived peptide, against ovarian cancer; and IO160, a neo antigen vaccine to treat myeloproliferative neoplasms (MPN). It utilizes T-win technology platform to discover, design, and validate new immune modulating vaccine candidates. The company is a spin off from the Center for Cancer Immune Therapy (CCIT), University of Copenhagen Herlev Hospital. IO Biotech is headquartered in Copenhagen, Denmark.
For a complete picture of IO-103’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
